Chronic daily headache

Expert Review of Neurotherapeutics

Volumn 8, Issue 3, 2008, Pages 361-384

  Nappi, Giuseppe ^b,c   Perrotta, Armando ^b,c   Rossi, Paolo ^a,d   Sandrini, Giorgio ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d INI   (Italy)

Author keywords

Chronic daily headache; Medication overuse headache; Prophylaxis

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BHT 3009; CODEINE; DOSULEPIN; ERGOTAMINE; FLUOXETINE; LONG ACTING DRUG; METOPROLOL; MUSCARINIC RECEPTOR BLOCKING AGENT; NADOLOL; NAPROXEN; NEUROLEPTIC AGENT; NORTRIPTYLINE; OPIATE; PAROXETINE; PLACEBO; PREDNISONE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; STEROID; TIMOLOL; TIZANIDINE; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGITATION; ANXIETY DISORDER; ASTHENIA; BLURRED VISION; BODY MASS; BRADYCARDIA; CARDIOTOXICITY; CHRONIC DAILY HEADACHE; CHRONIC TENSION HEADACHE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEPRESSION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG CONTRAINDICATION; DRUG DETOXIFICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FATIGUE; HALLUCINATION; HEMICRANIA CONTINUA; HUMAN; IMPOTENCE; INCREASED APPETITE; INSOMNIA; LETHARGY; MEMORY DISORDER; MIGRAINE; MONOTHERAPY; MUSCLE DISEASE; NEW DAILY PERSISTENT HEADACHE; NIGHTMARE; ORTHOSTATIC HYPOTENSION; PANIC; PATHOPHYSIOLOGY; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIMARY HEADACHE; RESTLESSNESS; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PROBLEM; SOMNOLENCE; STOMACH PAIN; TRANSFORMED MIGRAINE; VOMITING; WEIGHT GAIN; XEROSTOMIA;

COMBINED MODALITY THERAPY; CONTROLLED CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; FEMALE; HEADACHE DISORDERS; HUMANS; INCIDENCE; MALE; TREATMENT OUTCOME;

EID: 41649108291     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.3.361     Document Type: Review

References (197)

1. Olesen J, Tfelt-Hansen P, Ramadan N, Goadsby PJ, Welch KMA. The Headaches. Lippincott, Williams & Wilkins, Pennsylvania, PA, USA (2005).
2. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr. Pain Headache Rep. 5(6), 529-536 (2001).
3. Stovner Lj, Hagen K, Jensen R et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27(3), 193-210 (2007).
4. Sancisi E, Cevoli S, Pierangeli G et al.. Application of ICHD-II and revised diagnostic criteria to patients with chronic daily headache. Neurol. Sci. 28(1), 2-8 (2007).
5. Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache 43(4), 336-342 (2003).
6. Duru G, Auray JP, Gaudin AF et al. Impact of headache on quality of life in a general population survey in France (GRIM2000 Study). Headache 44, 571-580 (2004).
7. Meletiche DM, Lofland JH, Young WB. Quality-of-life differences between patients with episodic and transformed migraine. Headache 41(6), 573-578 (2001).
8. Stovner LJ, Hagen K. Prevalence, burden, and cost of headache disorders. Curr. Opin. Neurol. 19(3), 281-285 (2006).
9. International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 7(Suppl.), 1-96 (1988).
10. Solomon S, Lipton RB, Newman LC. Evaluation of chronic daily headache: comparison to criteria for chronic tension-type headache. Cephalalgia 12, 365-368 (1992).
11. Manzoni GC, Granella F, Sandrini G. Classification of chronic daily headache by International Headache Society criteria: limits and new proposal. Cephalalgia 15, 37-43 (1995).
12. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 2nd Edition. Cephalalgia 24(Suppl. 1), 9-160 (2004).
13. Silberstein SD, Olesen J, Bousser MG et al. The International Classification of Headache Disorders, 2nd edition (ICHD-II) - revision of criteria for 8.2 medication-overuse headache. Cephalalgia 25, 460-465 (2005).
14. Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB. Chronic daily headache: correlation between the 2004 and the 1988 International Headache Society diagnostic criteria. Headache 44, 684-691 (2004).
15. Headache Classification Committee of the International Headache Society. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26, 742-746 (2006).
16. Mathew NT. Transformed or evolutional migraine. Headache 27, 305-306 (1987).
17. Sandrini G, Manzoni GC, Zanferrari C, Nappi G. An epidemiological approach to nosography of chronic daily headache. Cephalalgia 13, 72-77 (1993).
18. Lipton RB, Pan J. Is migraine a progressive brain disease? JAMA 28, 493-494 (2004).
19. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 38, 497-506 (1998).
20. Katsarava Z, Schneeweiss S, Kurth T et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62, 788-790 (2004).
21. Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106, 81-89 (2003).
22. Bigal ME, Liberman JN, Lipton RB. Obesity and migraine: a population study. Neurology 66(4), 545-550 (2006).
23. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 67(2), 252-257 (2006).
24. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache 46(9), 1334-1343 (2006).
25. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology 60(8), 1308-1312 (2003).
26. Verri AP, Proietti Cecchini A, Galli C, Granella F, Sandrini G, Nappi G. Psychiatric comorbidity in chronic daily headache. Cephalalgia 18(Suppl. 21), 45-49 (1998).
27. Juang KD, Wang SJ, Fuh JL, Lu SR, Su TP. Comorbidity of depressive and anxiety disorders in chronic daily headache and its subtypes. Headache 40(10), 818-823 (2000).
28. Boes CJ, Capobianco DJ. Chronic migraine and medication-overuse headache through the ages. Cephalalgia 25(5), 378-390 (2005).
29. Limmroth V, Katsarava Z, Fritsche G et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 59, 1011-1014 (2002).
30. Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 61(2), 160-164 (2003).
31. Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 62(8), 1338-1342 (2004).
32. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic over a 3-year period. Headache 43, 14-18 (2003).
33. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes. Cephalalgia 24(6), 483-490 (2004).
34. Diener HC, Dahlöf CGH. Headache associated with chronic use of substances. In: The Headaches, 2nd Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott, Williams & Wilkins, PA, USA, 871-878 (1999).
35. Meskunas CA, Tepper SJ, Rapoport AM et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 46, 766-772 (2006).
36. Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 57, 1694-1698 (2001).
37. Welch KM. Contemporary concepts of migraine pathogenesis. Neurology 61(8 Suppl. 4), S2-S8 (2003).
38. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 4, 629-637 (2001).
39. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 3, 475-483 (2004).
40. Calabresi P, Cupini LM. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol. Sci. 26, 62-68 (2005).
41. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89(2-3), 107-110 (2001).
42. Ayzenberg I, Obermann M, Nyhuis P et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 26(9), 1106-1114 (2006).
43. Ji RR, Woolf CJ. Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol. Dis. 8, 1-10 (2001).
44. Pini LA, Sandrini M, Vitale G. The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur. J. Pharmacol. 308(1), 31-40 (1996).
45. Sandrini M, Vitale G, Pini LA. Central antinociceptive activity of acetylsalicylic acid is modulated by brain serotonin receptor subtypes. Pharmacology 65, 193-197 (2002).
46. 3 receptor subtypes in the antinociceptive effect of paracetamol. Inflamm. Res. 52, 347-352 (2003).
47. Dobson CF, Tohyama Y, Diksic M, Hamel E. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 24, 2-11 (2004).
48. Reuter U, Salomone S, Ickenstein GW, Waeber C. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia 24, 398-407 (2004).
49. Urban MO, Gebhart GF. Supraspinal contributions to hyperalgesia. Proc. Natl Acad. Sci. USA 96, 7687-7692 (1999).
50. Millan MJ. Descending control of pain. Prog. Neurobiol. 66, 355-474 (2002).
51. Porreca F, Ossipov MH, Gebhart GF. Chronic pain and medullary descending facilitation. Trends Neurosci. 25, 319-325 (2002).
52. Fumal A, Laureys S, Di Clemente L et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 129(Pt 2), 543-550 (2006).
53. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 43, 179-190 (2003).
54. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache 41, 303-309 (2001).
55. Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener HC, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 25, 12-15 (2005). •• Provides highly important information on the prognosis of medication-overuse headache.
56. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 26, 1192-1198 (2006).
57. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 66, 1894-1898 (2006).
58. Hering R, Steiner TJ. Abrupt outpatient withdrawal of medication in analgesic-abusing migraineurs. Lancet 337, 1442-1443 (1991).
59. Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia 26, 1097-1105 (2006).
60. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 57, 1694-1698 (2001).
61. Mathew NT. Amelioration of ergotamine withdrawal with naproxen. Headache 27, 130-133 (1987).
62. Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 20, 107-113 (2000).
63. Stellar S, Ahrens SP, Meibohm AR et al. Migraine prevention with timolol. A double-blind crossover study. JAMA 252, 2576-2580 (1984).
64. Fuller GN, Guiloff RJ. Propanolol in acute migraine: a controlled study. Cephalalgia 10, 229-233 (1990).
65. Snow V, Weiss K, Wall EM, Mottur-Pilson C. American Academy of Family Physicians; American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann. Intern. Med. 137, 840-849 (2002).
66. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55(6), 754-762 (2000).
67. Pascual J, Rivas MT, Leira R. Testing the combination ?-blocker plus topiramate in refractory migraine. Acta Neurol. Scand. 115(2), 81-83 (2007).
68. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 42, 510-514 (2002).
69. Saper JR, Silberstein SD, Lake AE 3rd, Winters ME. Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 34, 497-502 (1994).
70. Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology 44(11 Suppl. 9), S6-S10 (1994).
71. Saper JR, Winner PK, Lake AE 3rd. An open-label dose-titration study of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. Headache 41(4), 357-368 (2001).
72. Saper JR, Lake AE 3rd, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 42, 470-482 (2002).
73. Spira PJ, Beran RG; Australian Gabapentin Chronic Daily Headache Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 61, 1753-1759 (2003).
74. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache 31, 71-74 (1991).
75. Freitag FG, Diamond S, Diamond ML, Urban GJ. Divalproex in the long-term treatment of chronic daily headache. Headache 41, 271-278 (2001).
76. Brandes JL, Saper JR, Diamond M et al. MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 291, 965-973 (2004).
77. Silberstein SD, Neto W, Schmitt J, Jacobs D, MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. 61, 490-495 (2004).
78. Silberstein SD, Lipton RB, Dodick DW et al. Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47(2), 170-180 (2007). • Large pivotal trial providing data on the efficacy of topiramate in treatment of chronic migraine.
79. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ; TOPMAT-MIG-201(TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27(7), 814-823 (2007).
80. Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: reducing the risk for chronic forms of headache. Headache 47(1), 13-21 (2007).
81. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type-A in pain management. Headache 43(Suppl. 1), S9-S15 (2003).
82. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44, 35-43 (2004).
83. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 40(6), 445-450 (2000).
84. Anand KS, Prasad A, Singh MM, Sharma S, Bala K. Botulinum toxin type A in prophylactic treatment of migraine. Am. J. Ther. 13(3), 183-187 (2006).
85. Relja M, Poole AC, Schoenen J, Pascual J, Lei X, Thompson C. European BoNTA Headache Study Group. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 27(6), 492-503 (2007).
86. Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM; BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 47(4), 486-499 (2007).
87. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC; BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. 80(9), 1126-1137 (2005).
88. Mathew NT, Frishberg BM, Gawel M et al.. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 45, 293-307 (2005).
89. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population: a prevalence study. J. Clin. Epidemiol. 44, 1147-1157 (1991).
90. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA 279, 381-383 (1998).
91. Rasmussen BK, Lipton RB. Epidemiology of tension-type headache. In: The Headaches (2nd Edition). Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott, Williams & Wilkins, PA, USA, 545-550 (2000).
92. Jensen R, Symon D. Epidemiology of tension-type headaches. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan N et al. (Eds). Lippincott, Williams & Wilkins, PA, USA, 621-624 (2005).
93. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey. Eur. J. Epidemiol. 20, 243-249 (2005). •• This study evaluated the evolution of prevalence of chronic tension-type headache (CTTH) over more than 10 years.
94. Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J. Occup. Environ. Med. 39, 320-327 (1997).
95. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Incidence of primary headache: a Danish epidemiologic follow-up study. Am. J. Epidemiol. 161, 1066-1073 (2005).
96. Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Prognosis of migraine and tension-type headache: a population-based follow-up study. Neurology 65, 580-585 (2005).
97. Jensen R, Becker WJ. Symptomatology of tension-type headaches. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan N et al. (Eds). Lippincott, Williams & Wilkins, PA, USA, 685-692 (2005).
98. Peatfield RC, Edmeads JG. General approach to treatment of tension-type headaches. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan N et al. (Eds). Lippincott, Williams & Wilkins, PA, USA, 707-710 (2005).
99. Janke EA, Holroyd KA, Romanek K. Depression increases onset of tension-type headache following laboratory stress. Pain 111, 230-238 (2004).
100. Ashina S, Bendtsen L, Ashina M. Pathophysiology of tension-type headache. Curr. Pain Headache Rep. 9, 415-422 (2005).
101. Bendtsen L, Schoenen J. Synthesis of tension-type headache mechanisms. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan N et al. (Eds). Lippincott, Williams & Wilkins, PA, USA, 677-681 (2005).
102. Pielsticker A, Haag G, Zaudig M, Lautenbacher S. Impairment of pain inhibition in chronic tension-type headache. Pain 118(1-2), 215-223 (2005). • This study provided evidence for defective supraspinal control of pain in CTTH.
103. Schmidt-Wilcke T, Leinisch E, Straube A, et al. Gray matter decrease in patients with chronic tension type headache. Neurology 65, 1483-1486 (2005). • This study provided evidence of structural changes in the gray matter of patients with CTTH.
104. Mathew NT, Bendtsen L. Prophylactic pharmacotherapy of tension-type headache. In: The Headaches, 2nd Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott, Williams & Wilkins, PA, USA, 667-774 (2000).
105. Holroyd KA, Martin PR. Psychological treatments for tension-type headache In: The Headaches (2nd Edition). Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott, Williams & Wilkins, PA, USA, 643-649 (2000).
106. Biondi DM. Physical treatments for headache: a structured review. Headache 45, 738-746 (2005).
107. Lenssinck ML, Damen L, Verhagen AP et al. The effectiveness of physiotherapy and manipulation in patients with tensiontype headache: a systematic review. Pain 112, 381-388 (2004).
108. Holroyd KA, O'Donnell FJ, Stensland M et al. Management of chronic tension-type headache with tricyclic antidepressant medication, stress-management therapy, and their combination: a randomized controlled trial. JAMA 285, 2208-2215 (2001).
109. Leinisch-Dahlke E, Jurgens T, Bogdahn U et al. Greater occipital nerve block is ineffective in chronic tension-type headache. Cephalalgia 25, 704-708 (2005).
110. Melchart D, Streng A, Hoppe A et al. Acupuncture in patients with tension-type headache: randomised controlled trial. Br. Med. J. 331, 376-382 (2005).
111. Bendtsen L, Jensen R, Olesen J. A nonselective (amitriptyline), but not a selective (citalopram) serotonin reuptake inhibitor is effective in the treatment of chronic tension-type headache. J. Neurol. Neurosurg. Psychiatr. 61, 285-290 (1996).
112. Boz C, Altunayoglu V, Velioglu S, Ozmenoglu M. Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients. Headache 4, 72-78 (2002).
113. Ashina S, Bendtsen L, Jensen R. Analgesic effect of amitriptyline in chronic tensiontype headache is not directly related to serotonin reuptake inhibition. Pain 108, 108-114 (2004).
114. Bendtsen L, Jensen R. Amitriptyline reduces myofascial tenderness in patients with chronic tension-type headache. Cephalalgia 20, 603-610 (2000).
115. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 62, 1706-1711 (2004)
116. Singh NN, Misra S. Sertraline in chronic tension-type headache. J. Assoc. Physicians India 50, 873-878 (2002)
117. Silberstein SD, Gobel H, Jensen R et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 26(7), 790-800 (2006).
118. Padberg M, de Bruijn SF, de Haan RJ, Tavy DL. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 24, 675-680 (2004).
119. Silberstein SD, Göbel H, Jensen R et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 26(7), 790-800 (2006).
120. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. BOTOX CDH Study Group. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45(4), 315-324 (2005).
121. Rasmussen BK, Jensen R, Schroll M, Olesen J. Impact of headache in a general population: a prevalence study. J. Clin. Epidemiol. 44, 1147-1157 (1991).
122. Ward TN. Medication overuse headache. Prim. Care 31, 369-380 (2004)
123. Mathew N. Tension-type headache. Curr. Neurol. Neurosci. Rep. 6, 100-105 (2006). • A comprehensive review of the management of TTH.
124. Jensen R. Diagnosis, epidemiology and impact of tension-type headache. Curr. Pain Headache Rep. 7, 455-459 (2003).
125. Eisenberg DM, Kessler RC, Van Rompay MI et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann. Intern. Med. 135, 344-351 (2001).
126. Long L, Huntley, A, Ernst E. Which complementary and alternative therapies benefit which conditions? A survey of the opinions of 223 professional organizations. Complement. Ther. Med. 9, 178-185 (2001)
127. Rossi P, Di Lorenzo G, Faroni J, Malpezzi MG, Cesarino F, Nappi G. Use of complementary and alternative medicine by patients with chronic tension-type headache: results of a headache clinic survey. Headache 46, 622-631 (2006).
128. Nash JM, Willliams DM, Nicholson R, Trask PC. The contribution of pain-related anxiety to disability from headache. J. Behav. Med. 29, 61-67 (2006).
129. Bendtsen L, Jensen R. Tension-type headache. The most common, but also the most neglected, headache disorder. Curr. Opin. Neurol. 19, 305-309 (2006).
130. Fernandez-de-las-Penas C, Alonso-Blanco C, Cuadrado ML, Gerwin RD, Pareja JA. Trigger points in the suboccipital muscles and forward head posture in tension-type headache. Headache 46, 454-460 (2006).
131. Lenssinck ML, Damen L, Verhagen AP, Berger MY, Passchier J, Koes BW. The effectiveness of physiotherapy and manipulation in patients with tension-type headache: a systematic review. Pain 112, 381-386 (2004).
132. Bromfort G, Nilsson N, Haas M et al. Non-invasive physical treatments for chronic/recurrent headache. Cochrane Database Syst. Rev. CD001878 (2004).
133. Torelli P, Jensen R, Olesen J. Physiotherapy for tension-type headache: a controlled study. Cephalalgia 24, 29-37 (2004).
134. Van Ettekoven H, Lucas C. Efficacy of physiotherapy including a craniocervical training programme for tension-type headache: a randomized clinical trial. Cephalalgia 26, 983-991 (2006). •• A well conducted innovative trial of physiotherapy in TTH.
135. Soderberg E, Carlsson J, Stener-Victorin E. Chronic tension-type headache treated with acupuncture, physical training and relaxation training. Between-group differences. Cephalalgia 26, 1320-1329 (2006).
136. Melchart D, Linde K, Fischer P et al. Acupuncture for idiopathic headache. Cochrane Database Syst. Rev. CD001218 (2001).
137. Xue CC, Dong L, Polus B et al. Electroacupuncture for tension-type headache on distal acupoints only : a randomized controlled crossover trial. Headache 44, 333-341 (2004).
138. Vickers AJ, Rees RW, Zollman CE et al. Acupuncture for chronic headache disorders in primary care: large pragmatic randomized trial. Br. Med. J. 3, 1-6 (2004).
139. Melchart D, Weidenhammer W, Streng A, Hoppe A, Pfaffenrath V, Linde K. Acupuncture for chronic headaches: an epidemiological study. Headache 46, 632-641 (2006)
140. Karst M, Rehnard M, Thum P, Wiese B, Rollnik J, Fink M. Needle acupuncture in tension-type headache: a randomized placebo controlled study. Cephalalgia 21(Suppl. 6), 637-642 (2001).
141. Cummings M. No difference between acupuncture and sham in chronic tension-type headache. Acupunct. Med. 19, 51-53 (2001).
142. Astin JA, Ernst E. The effectiveness of spinal manipulation for the treatment of headache disorders: a systematic review of randomized clinical trials. Cephalalgia 22, 617-623 (2002).
143. Ernst E. Manual therapies for pain control: chiropractic and massage. Clin. J. Pain. 20, 8-12 (2004).
144. Fernandez-de-las-Penas C, Alonso-Blanco C, Cuadrado ML, Miangolarra JC, Barriga FJ, Pareja JA. Are manual therapies effective in reducing pain from tension-type headache ? A systematic review. Clin. J. Pain 22, 278-285 (2006). • A comprehensive systematic review of the effectiveness of manual therapies in TTH.
145. Penzien DB, Rains JC, Andrasik F. Behavioral management of recurrent headache: three decades of experience and empiricism. Appl. Psychophysiol. Biofeedback 27, 163-181 (2002).
146. Rains JC, Penzien DB, McCrory DC, Gray RN. Behavioral headache treatment: history, review of the empirical literature and methodological critique. Headache 45(Suppl. 2), S92-S109 (2005). • A comprehensive and interesting review of behavioral treatment for headache.
147. McCrory DC, Penzien DB, Hasselblad V, Gray RN, for the Duke University Evidence-based Practice Center, Center for Clinical Health Policy Research, Foundation for Chiropractic Education and Research. Evidence Report: Behavioral and Physical Treatments for Tension-type and Cervicogenic Headache. Foundation for Chiropractic Education and Research, Des Moines, IA, USA (2001).
148. Bogaards EB, ter Kuile MM. Treatment of recurrent tension-type headache: a meta-analytic review. Clin. J. Pain 10, 174-190 (1994).
149. Haddock CK, Rowan AB, Andrasik F, Wilson PG, Talcott GW, Stein RJ. Home-based behavioural treatments for chronic benign headache: a meta-analysis of controlled trials. Cephalalgia 17, 113-118 (1997).
150. Devineni T, Blanchard EB. A randomized controlled trial of an internet-based treatment for chronic headache. Behav. Res. Ther. 43, 277-292 (2005).
151. Trautmann E, Lackshewitz H, Kroner-Herwig B. Psychological treatment of recurrent headache in children and adolescents. Cephalalgia 26, 1411-1426 (2006).
152. Sjastaad O, Spierings EL. "Hemicrania continua". Another headache absolutely responsive to indomethacin. Cephalalgia 4, 65-70 (1984).
153. Peres MF, Silberstein SD, Nahmias S et al. Hemicrania continua is not that rare. Neurology 57, 948-951 (2001).
154. Sjastaad O, Bakketeig LS. The rare, unilateral headaches. Vaga study of headache epidemiology. J. Headache Pain 8, 19-27 (2007).
155. Pareja J, Vincent M, Antonaci F, Sjaastad O. Hemicrania continua: diagnostic criteria and nosologic status. Cephalalgia 21, 874-877 (2001).
156. Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic features, including new cases. Brain 120, 193-209 (1997).
157. Matharu MS, Cohen AS, McGonigle DJ, Ward N, Frackowiak, RS, Goadsby PJ. Posterior hypothalamic and brainstem activation in hemicrania continua. Headache 44, 747-761 (2004).
158. Spierings ELH, Sjaastad O. Hamicrania continua is not that rare. Neurology 59, 476 (2002).
159. Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: the "Indotest". Headache 8, 235-236 (1998).
160. Pareja JA, Caminero AB, Franco E, Casado JL, Pascual J, Sanchez del Rio M. Dose, efficacy and tolerability of long-term indomethacin reatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia 21, 906-910 (2001). • The only available study investigating long-term management of hemicrania continua with indomethacin.
161. Dodick D. Indomethacin-responsive headache syndromes. Curr. Pain Headache Rep. 8, 19-26 (2004).
162. Sjaastad O. Chonic paroxysmal hemicrania, hemicrania continua and SUNCT: the fate of the first three described cases. J. Headache Pain 7, 151-156 (2006).
163. Sjaastad O, Antonaci F. A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua. Headache 35, 549-550 (1995).
164. Peres MF, Silberstein SD. Hemicrania continua responds to cyclooxygenase-2 inhibitors. Headache 42, 530-531 (2002).
165. Peres MF, Zuckerman E. Hemicrania continua responsive to rofecoxib. Cephalalgia 20, 130-131 (2000).
166. Lenzer J. FDA advisers warn: COX2-inhibitors increased risk of heart attack and stroke. Br. Med. J. 330, 440 (2005).
167. Rozen TD. Melatonin responsive hemicrania continua. Headache 46, 1203-1208 (2006).
168. Spears RC. Hemicrania continua: a case in which a patient experienced complete relief on melatonin. Headache 46, 524-527 (2006).
169. Matharu MS, Bradbury P, Swash M. Hemicrania continua: side alternation and response to topiramate. Cephalalgia 26, 341-344 (2005).
170. Brighina F, Palermo A, Cosentino G, Fierro B. Prophylaxis of hemicrania continua: two new cases effectively treated with topiramate. Headache 47, 441-443 (2007).
171. Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalalgias and hemicrania continua. Drugs 63, 1637-1677 (2003). • A review on the management of hemicrania continua.
172. Rajabally YA, Jacob S. Hemicrania continua responsive to verapamil. Headache 45, 1082-1087 (2005).
173. Antonaci F, Pareva JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: lack of efficacy of sumatriptan. Headache 38, 197-200 (1996).
174. Bordini C, Antonaci F, Stovner LJ, Schrader H, Sjaastad O. "Hemicrania continua": a clinical review. Headache 31, 20-26 (1991).
175. Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: anaesthetic blockades of pericranial nerves. Funct. Neurol. 1, 11-15 (1997).
176. Schwedt TJ, Dodick DW, Hentz J, Trentman TL, Zimmerman RS. Occipital nerve stimulation for chronic headache - long term safety and efficacy. Cephalalgia 27, 153-157 (2007).
177. Rossi P, Faroni V, Tassorelli C, Nappi G. Diagnostic delays and mismanagement of hemicrania continua. Cephalalgia 6, 700 (2007).
178. Pareja JA, Antonaci F, Vincent M. The hemicrania continua diagnosis. Cephalalgia 21, 940-946 (2001).
179. Diaz-Mitorna F, Vanast WJ, Tirrel DLJ. Increased frequency of Epstein-Barr virus excretion in patients with new-daily persistent headache. Lancet 1, 411-415 (1987).
180. Vanast WJ. New daily persistent headache: definition of a benign syndrome. Headache 26, 317 (1986).
181. Li D, Rozen TD. The clinical characteristics of new daily-persistent headache. Cephalalgia 22, 66-69 (2002).
182. Rozen T, Swidan SZ. Elevation of CSF tumor necrosis factor ? levels in new daily-persistent headache and treatment refractory chronic migraine. Headache 47, 1050-1052 (2007).
183. Rozen TD, Roth JM, Denenberg N. Cervical spine joint hypermobility: a possible predisposing factor for new daily-persistent headache. Cephalalgia 26, 1182-1185 (2006).
184. Goadsby PJ, Boes C. New daily persistent headache. J. Neurol. Neurosurg. Psychiatr. 72(Suppl. II), ii6-ii9 (2002).
185. Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily-persistent headache (NDPH): 30 cases in Japan. Cephalalgia 24(11), 955-959 (2004).
186. Meineri P, Torre E, Rota E, Grasso E. New daily-persistent headache: clinical and serological characteristics in a retrospective study. Neurol. Sci. 25, S281-S282 (2004).
187. Evans RW, Rozen TD. Etiology and treatment of new daily persistent headache. Headache 41, 830-832 (2001).
188. Sjaastad O. "Chronic daily headache" ("cefalea cronica quotidiana"). Cephalalgia 5(Suppl. 2), 191-193 (1985).
189. Nappi G, Savoldi F. Headache: Diagnostic System and Taxonomic Criteria. Libbey J (Ed.). John Libbey Eurotext, London (1985).
190. Sandrini G, Cecchini AP, Tassorelli C, Nappi G. Diagnostic issues in chronic daily headache. Curr. Pain Headache Rep. 5(6), 551-556 (2001).
191. Popeney CA, Aló KM. Peripheral neurostimulation for the treatment of chronic, disabling transformed migraine. Headache 43(4), 369-375 (2003).
192. Matharu MS, Bartsch T, Ward N, Frackowiak RS, Weiner R, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: A PET study. Brain 127, 220-230 (2004).
193. Schwedt TJ, Dodick DW. Occipital nerve stimulation for TACs: pain relief and persistence of autonomic features. Cephalagia 26, 1025-1027 (2006).
194. Schoenen J, Di Clemente L, Vandenheede M et al. Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action. Brain 128, 940-947 (2005).
195. Leone M, Franzini A, D'Andrea G, Broggi G, Casucci G, Bussone G. Deep brain stimulation to relieve drug-resistant SUNCT. Ann. Neurol. 57, 924-927 (2005).
196. Leone M, May A, Franzini A et al. Deep brain stimulation for intractable chronic cluster headache: proposals for patient selection. Cephalalgia 24, 934-937 (2004).
197. BASH guidelines for the management of headache. Management of tension-type headache 37 (2007) www.bash.org.uk